Recommendations Developed for Management of Acute Liver Failure
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 12, 2023 -- In a clinical guideline issued by the American College of Gastroenterology and published in the July issue of the American Journal of Gastroenterology, recommendations are presented for the identification, treatment, and management of acute liver failure (ALF).
Alexandra Shingina, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues reviewed the scientific evidence to develop recommendations for identification, treatment, and management of ALF.
The authors developed 10 recommendations (four strong; six conditional) and summarized expert opinions using key concepts when no robust evidence was available. The strong recommendations included use of norepinephrine as the first-line vasopressor for hypotension refractory to fluid resuscitation; early administration of N-acetylcysteine (NAC) in patients with suspected N-acetyl-p-aminophenol (APAP) toxicity; initiation of intravenous NAC in patients with non-APAP ALF; and starting antiviral therapy in patients with ALF due to reactivation of hepatitis B virus. Conditional recommendations included not using routine correction of coagulopathy in the absence of active bleeding or an impending high-risk procedure and not using prophylactic antimicrobial agents routinely, given no improvement in either rate of blood stream infection or 21-day mortality. In terms of general management, comprehensive testing is essential to elucidate a diagnosis and exclude underlying chronic liver disease.
"ALF is a medical emergency and is potentially reversible if recognized and treated early," the authors write. "ALF must be differentiated from acute-on-chronic liver failure and decompensated cirrhosis because management is vastly different."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Childhood Physical Activity Levels Tied to Risk for Liver Disease in Young Adults
WEDNESDAY, June 19, 2024 -- Increasing physical activity during childhood may independently lower the risk for liver disease in young adulthood, according to a study published...
Survodutide Tied to Significant Improvement in Fatty Liver Disease
MONDAY, June 17, 2024 -- Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.